Chest
-
Randomized Controlled Trial
Solriamfetol for the treatment of excessive sleepiness in obstructive sleep apnea: A placebo-controlled randomized-withdrawal study.
Excessive sleepiness (ES) is a common symptom of OSA, which often persists despite primary OSA therapy. This phase III randomized withdrawal trial evaluated solriamfetol (JZP-110) for the treatment of ES in adults with OSA. ⋯ This study demonstrated maintenance of solriamfetol efficacy and safety over 6 weeks.